Purple Biotech announces their novel CAPTN-3 tri-specific antibody platform at EACR 2025. The company focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, a humanized monoclonal antibody that blocks CEACAM1 to target multiple cancer indications. NT219, a dual inhibitor small molecule, demonstrated anti-tumor activity in a Phase 1 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Purple Biotech is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells, presenting a novel mechanism for mounting an optimal anti-tumoral immune response within the tumor microenvironment. IM1240, the first tri-specific antibody targeting the 5T4 antigen, is in development to address solid tumors associated with advanced disease. For more information, visit Purple Biotech’s corporate headquarters in Rehovot, Israel.
Read more from finance.yahoo.com
